Approved indications: Uzedy is FDA-approved in adults for the treatment of schizophrenia and for the maintenance treatment of bipolar I disorder, either as monotherapy or together with lithium or valproate.

Off-label uses: Because Uzedy is a newer long-acting risperidone injection with specific adult approvals, off-label use has been limited; some clinicians may extrapolate data from oral and other long-acting risperidone products to consider it in closely related psychotic conditions (such as schizoaffective disorder) when a long-acting risperidone is desired, but direct high-quality trial data for these off-label uses are lacking.

Efficacy in schizophrenia: Blood levels reach the therapeutic range within about 6–24 hours after injection, and clinical trials show a marked reduction in the risk of relapse and a high proportion of patients remaining stable over 6–12 months when injections are kept on schedule, with both once-monthly and once-every-2-month regimens effective.

Efficacy in bipolar I disorder: Uzedy is used for maintenance, meaning it helps prevent future mood episodes (especially manic or mixed episodes) rather than treating a single acute episode, with benefits expected over weeks to months as the risk of new mood episodes and hospitalizations is reduced when combined with ongoing mood-stabilizing treatment as prescribed.

Comparison with similar drugs: Overall antipsychotic efficacy is comparable to other second-generation long-acting injectables (such as paliperidone or aripiprazole products) when patients have previously responded to oral risperidone, while Uzedy’s subcutaneous route, relatively small injection volume, and option for 1- or 2-month dosing intervals mainly affect convenience and adherence rather than making it clearly stronger or weaker than other agents.

General dosing approach: Before starting Uzedy, tolerability to oral risperidone is usually established; a healthcare professional then chooses the Uzedy dose based on the effective daily oral dose and the condition being treated.

Dosing for schizophrenia: For adults stabilized on 2–5 mg/day of oral risperidone, typical Uzedy doses range from 50–125 mg given once monthly or 100–250 mg given once every 2 months as a subcutaneous injection, with the exact strength selected to match the prior oral dose and clinical response.

Dosing for bipolar I maintenance: For adults with bipolar I disorder who have tolerated oral risperidone, common maintenance doses are 50–100 mg given once monthly under the skin, with the specific choice depending on the effective oral dose and how well symptoms are controlled.

Administration details: Uzedy is administered only by a healthcare professional as a single-use prefilled syringe injected under the skin of the abdomen or upper arm; there is no need for an oral loading regimen or overlapping oral risperidone when initiating, and doses should not be given more often than the prescribed once-monthly or once-every-2-month schedule.

Special dosing considerations: In people with significant kidney or liver impairment, prescribers typically use lower oral risperidone doses and titrate carefully before converting to Uzedy, and they may choose a lower injection dose or slower adjustments; dose changes are usually made gradually and based on both symptom control and side effects.

Missed doses: If an injection visit is missed, the general instruction is to receive the next Uzedy dose as soon as possible and then continue on the regular schedule, without giving extra injections or shortening the interval, while the clinician assesses for any return of symptoms.

Overdose: Because Uzedy is given as a clinic-administered prefilled syringe, overdose is uncommon, but if too much is given or if someone else receives the medicine accidentally, emergency medical care should be sought immediately or poison control should be contacted, since very high exposures to risperidone can cause severe drowsiness, marked blood pressure changes, serious heart rhythm problems, or pronounced movement disorders.

Common side effects: Frequently reported effects include weight gain, increased appetite, sleepiness or fatigue, dizziness, restlessness or other movement symptoms (such as tremor or stiffness), increased saliva or drooling, stomach or digestive upset, and injection-site reactions like small nodules, itching, redness, or swelling; these are usually mild to moderate and tend to appear in the first weeks to months of treatment.

Metabolic and hormonal effects: Like other atypical antipsychotics, Uzedy can raise blood sugar, worsen or trigger diabetes, increase blood lipids, and cause weight gain, so clinicians typically monitor weight, waist size, and blood tests (glucose and cholesterol) over time; it can also increase prolactin, which may lead to missed periods, breast milk production, breast enlargement, reduced fertility, or sexual dysfunction in some people.

Serious or rare adverse effects: Serious problems that require urgent medical attention include signs of stroke (sudden weakness, trouble speaking, facial droop), high fever with severe muscle stiffness and confusion (possible neuroleptic malignant syndrome), uncontrollable body or facial movements (tardive dyskinesia), very high blood sugar (extreme thirst, frequent urination, weakness, fruity breath), severe allergic reactions (rash, swelling of face or tongue, trouble breathing), fainting or chest pain, seizures, signs of severe infection (fever, sore throat, unusual bruising, or weakness that might reflect low white blood cells), or a painful prolonged erection.

Warnings and special populations: Uzedy carries the same boxed warning as other antipsychotics for increased risk of death in older adults with dementia-related psychosis and is not approved for that use; it should be used cautiously and at adjusted doses in people with kidney or liver impairment, in those with a history of heart disease, stroke, seizures, low white blood cell counts, diabetes, or high cholesterol, and in patients with Parkinson’s disease or dementia with Lewy bodies due to increased sensitivity to side effects.

Pregnancy and breastfeeding: Use during the third trimester of pregnancy can cause symptoms such as muscle stiffness, tremor, sleepiness, or feeding and breathing problems in newborns, so risks and benefits must be carefully weighed; if used while breastfeeding, infants should be monitored for excessive sleepiness, poor feeding, or unusual movements.

Overall safety profile: The safety of Uzedy is generally similar to oral risperidone and other second-generation long-acting antipsychotics, with added local injection-site reactions but no need for very large intramuscular injections; most side effects can be managed with dose adjustments, monitoring, or switching therapies when needed.

Reporting and staying informed: Side effects should be reported to the prescribing clinician and can also be reported directly to the FDA’s MedWatch program or to the manufacturer; patients and clinicians can check the FDA website and the official Uzedy prescribing information for up-to-date safety alerts and recommendations.

Metabolism-related interactions: Medicines that strongly inhibit CYP2D6 (such as fluoxetine or paroxetine and some other antidepressants) can increase risperidone levels and may raise the risk of side effects, while strong CYP3A4 inducers (such as carbamazepine, phenytoin, rifampin, and some anticonvulsants or herbal products like St John’s wort) can lower risperidone levels and reduce effectiveness, so prescribers often adjust therapy or choose alternatives.

CNS depressants, alcohol, and blood pressure medicines: Combining Uzedy with alcohol, opioids, benzodiazepines, sedating antihistamines, sleep aids, or other central nervous system depressants can increase drowsiness, dizziness, and risk of falls or breathing problems; Uzedy can also enhance the blood pressure–lowering effect of antihypertensive drugs, so blood pressure should be monitored, especially when therapy is started or doses are changed.

Dopamine-related drugs and movement medicines: Uzedy may counteract the effects of dopamine agonists used for Parkinson’s disease or restless legs syndrome (such as levodopa, pramipexole, or ropinirole), and dose changes in either Uzedy or stimulants like methylphenidate can increase the risk of movement side effects, so careful coordination between prescribers is important.

Heart rhythm and QT-prolonging drugs: Risperidone has a small potential to prolong the QT interval on the electrocardiogram, so caution is advised when Uzedy is used with other QT-prolonging medications (such as certain antiarrhythmics, some antibiotics, older antipsychotics, or some antidepressants) or in patients with known heart rhythm problems, low potassium or magnesium, or a strong cardiac history; in higher-risk situations, an ECG and electrolyte monitoring may be recommended.

OTC medicines and supplements: Many over-the-counter products, including sleep aids, cold and allergy medicines, and herbal supplements, can add sedation or interact via liver enzymes, so patients should check with a pharmacist or clinician before starting new nonprescription products while on Uzedy.

Medical conditions requiring precautions: Extra caution and closer monitoring are needed in patients with cardiovascular or cerebrovascular disease, a history of stroke or transient ischemic attack, diabetes or prediabetes, high cholesterol, obesity, seizure disorders, prior low white blood cell counts, prolactin-dependent tumors (such as some breast cancers), Parkinson’s disease, or dementia with Lewy bodies.

Monitoring needs: Typical monitoring while on Uzedy includes weight and body mass index, fasting glucose or hemoglobin A1c, lipid profile, blood pressure (including standing measurements in patients at risk of orthostatic hypotension), assessment for abnormal movements, and periodic blood counts in people with a history of low white blood cells; baseline and follow-up ECGs may be considered in patients with cardiac risk factors or on other QT-prolonging drugs.

Q: What is Uzedy used for?
A: Uzedy is a long-acting injection of the antipsychotic medicine risperidone used in adults to treat schizophrenia and to help prevent future mood episodes in bipolar I disorder, often together with other mood-stabilizing medicines.

Q: How often will I need to get the Uzedy shot?
A: Depending on the dose your clinician chooses, you will receive Uzedy as a small injection under the skin either once a month or once every 2 months, on a regular schedule.

Q: Will I still need to take antipsychotic pills after starting Uzedy?
A: Once tolerability to oral risperidone has been confirmed and Uzedy is started, most people do not need ongoing daily risperidone tablets for maintenance, although your clinician may keep or add other medicines (such as mood stabilizers or antidepressants) if needed.

Q: How soon will I notice a difference after my first Uzedy injection?
A: Therapeutic levels are reached within about a day, but improvements in symptoms or stability typically appear gradually over days to weeks, with the main benefit being fewer relapses and hospitalizations over the long term when injections are kept on schedule.

Q: What if I miss an appointment for my injection?
A: Contact your clinic as soon as you realize you have missed a dose so they can reschedule quickly; they will usually give the next injection as soon as possible and may monitor you more closely for any return of symptoms.

Q: Is Uzedy safe during pregnancy or breastfeeding?
A: Uzedy can be used in some pregnant or breastfeeding patients when the benefits outweigh the risks, but it may cause symptoms in newborns if used late in pregnancy and small amounts can pass into breast milk, so decisions should be made individually with your psychiatrist and obstetric or pediatric provider.

Q: Are the injections painful or will I have a lump?
A: Most people describe only brief discomfort at the injection site, and small, firm lumps or mild itching or redness under the skin are fairly common but usually mild and temporary; let your clinician know if pain, swelling, or skin changes are severe or do not improve.

Storage: If you are given Uzedy to keep at home, store the prefilled syringe in its original carton in a refrigerator (36°F–46°F / 2°C–8°C), protected from light, do not freeze it, and know that unopened cartons may be kept at room temperature (68°F–77°F / 20°C–25°C) for up to 90 days and then either used or returned to the refrigerator within that 90-day window.

Handling: Do not open the carton, remove the needle cap, or attempt to inject Uzedy yourself unless your healthcare provider has specifically trained you; keep all syringes out of sight and reach of children and pets.

Disposal: Used syringes and needles should go into a puncture-resistant sharps container, not into household trash or recycling; follow instructions from your clinic, pharmacy, or local waste authority about sharps disposal or community take-back programs, and never recap or reuse needles.